Genome & Company Statistics

Total Valuation

Genome & Company has a market cap or net worth of KRW 82.57 billion. The enterprise value is 86.44 billion.

Market Cap	82.57B
Enterprise Value	86.44B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Genome & Company has 30.98 million shares outstanding. The number of shares has decreased by -26.36% in one year.

Current Share Class	n/a
Shares Outstanding	30.98M
Shares Change (YoY)	-26.36%
Shares Change (QoQ)	+620.25%
Owned by Insiders (%)	21.51%
Owned by Institutions (%)	0.71%
Float	18.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.30
PB Ratio	1.63
P/TBV Ratio	3.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.42
EV / Sales	3.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.34

Financial Position

The company has a current ratio of 3.02, with a Debt / Equity ratio of 0.30.

Current Ratio	3.02
Quick Ratio	2.75
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-1.18
Interest Coverage	-12.29

Financial Efficiency

Return on equity (ROE) is -32.72% and return on invested capital (ROIC) is -17.22%.

Return on Equity (ROE)	-32.72%
Return on Assets (ROA)	-14.71%
Return on Capital (ROIC)	-17.22%
Revenue Per Employee	240.90M
Profits Per Employee	-356.71M
Employee Count	100
Asset Turnover	0.14
Inventory Turnover	2.59

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.66% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-51.66%
50-Day Moving Average	3,246.90
200-Day Moving Average	4,053.45
Relative Strength Index (RSI)	39.77
Average Volume (20 Days)	123,008

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genome & Company had revenue of KRW 24.09 billion and -35.67 billion in losses. Loss per share was -1,719.14.

Revenue	24.09B
Gross Profit	12.38B
Operating Income	-39.10B
Pretax Income	-40.18B
Net Income	-35.67B
EBITDA	-31.32B
EBIT	-39.10B
Loss Per Share	-1,719.14

Full Income Statement

Balance Sheet

The company has 78.21 billion in cash and 30.56 billion in debt, giving a net cash position of 47.65 billion or 1,537.87 per share.

Cash & Cash Equivalents	78.21B
Total Debt	30.56B
Net Cash	47.65B
Net Cash Per Share	1,537.87
Equity (Book Value)	102.10B
Book Value Per Share	1,633.28
Working Capital	59.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.01 billion and capital expenditures -6.90 billion, giving a free cash flow of -25.91 billion.

Operating Cash Flow	-19.01B
Capital Expenditures	-6.90B
Free Cash Flow	-25.91B
FCF Per Share	-836.29

Full Cash Flow Statement

Margins

Gross margin is 51.40%, with operating and profit margins of -162.31% and -148.07%.

Gross Margin	51.40%
Operating Margin	-162.31%
Pretax Margin	-166.79%
Profit Margin	-148.07%
EBITDA Margin	-130.02%
EBIT Margin	-162.31%
FCF Margin	n/a

Dividends & Yields

Genome & Company does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	26.36%
Shareholder Yield	26.36%
Earnings Yield	-64.51%
FCF Yield	-31.38%

Stock Splits

The last stock split was on August 6, 2024. It was a forward split with a ratio of 2.

Last Split Date	Aug 6, 2024
Split Type	Forward
Split Ratio	2

Scores

Genome & Company has an Altman Z-Score of -1.2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.2
Piotroski F-Score	n/a